Last $9.92 USD
Change Today -0.23 / -2.27%
Volume 195.4K
CEMP On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

cempra inc (CEMP) Snapshot

Open
$10.22
Previous Close
$10.15
Day High
$10.39
Day Low
$9.90
52 Week High
01/22/14 - $15.39
52 Week Low
04/15/14 - $8.10
Market Cap
329.8M
Average Volume 10 Days
119.1K
EPS TTM
$-1.92
Shares Outstanding
33.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CEMPRA INC (CEMP)

cempra inc (CEMP) Related Businessweek News

No Related Businessweek News Found

cempra inc (CEMP) Details

Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases in North America. Its two lead product candidates include Solithromycin (CEM-101), which is in a Phase III clinical trial for community-acquired bacterial pneumonia (CABP); and TAKSTA (CEM-102) that is in a Phase II clinical trial for prosthetic joint infections. The company also focuses on using its series of proprietary lead compounds from its novel macrolide library for uses, such as the treatment of chronic inflammatory diseases, endocrine diseases, and gastric motility disorders. It has collaborative research and development and license agreement with Optimer Pharmaceuticals, Inc. The company was formerly known as Cempra Holdings, LLC and changed its name to Cempra, Inc. in February 2012. Cempra, Inc. was founded in 2005 and is headquartered in Chapel Hill, North Carolina.

38 Employees
Last Reported Date: 02/28/14
Founded in 2005

cempra inc (CEMP) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $447.2K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $292.6K
Compensation as of Fiscal Year 2013.

cempra inc (CEMP) Key Developments

Cempra Initiates Phase 3 Clinical Trial in Patients with Uncomplicated Gonorrhea Infection

Cempra, Inc. announced the initiation of a Phase 3 clinical trial, called Solitaire-U, of a single 1000 mg dose of oral solithromycin in patients with uncomplicated Neisseria gonorrhea and chlamydia infections. The trial is being conducted in Australia and the U.S. and will enroll approximately 300 patients in a randomized 2-arm study with a single oral dose of 1000 mg of solithromycin compared with the standard of care, 500 mg of ceftriaxone administered intramuscularly and 1000 mg of oral azithromycin.

Cempra, Inc. - Analyst/Investor Day

Cempra, Inc. - Analyst/Investor Day

Cempra, Inc. Reports Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014

Cempra, Inc. reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported a net loss of $16.4 million, or $0.49 per basic and diluted share, compared to a net loss of $4.2 million, or $0.16 per basic and diluted share, for the same period in 2013. Revenues were $1,897,000 compared to $4,568,000 last year. Loss from operations was $15,906,000 compared to $3,841,000 last year. For the six months, the company reported net loss of $33.4 million, or $1.01 per basic and diluted share, compared to a net loss of $14.6 million, or $0.57 per basic and diluted share, for the comparable period in the six months ended June 30, 2013. Revenues were $4,980,000 compared to $4,568,000 last year. Loss from operations was $32,397,000 compared to $13,859,000 last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CEMP:US $9.92 USD -0.23

CEMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CEMP.
View Industry Companies
 

Industry Analysis

CEMP

Industry Average

Valuation CEMP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 40.1x
Price/Book 8.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 29.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEMPRA INC, please visit www.cempra.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.